Biggest Questions in Biotech
4 hours ago
- #biotech trends
- #future of pharma
- #AI in biology
- The article examines the biggest questions in biotech over the next decade, presenting bull and bear cases for each to clarify assumptions and aid company building.
- Key questions include: whether AI-driven bio neolabs will become large independent companies, if next-gen CROs will grow significantly, and if China will dominate global biotech.
- Other debates cover: the potential for increased US drug approvals, a collapse of incumbent drug distribution, biopharma becoming hyper-deflationary, and risks from asset-centric VC creating orphaned companies.
- Predictions favor: bio neolabs and next-gen CROs becoming large, China not becoming the global hub, more US drug approvals, and a shift away from traditional drug distribution, while rejecting near-term hyper-deflation in biopharma.
- The goal is to make implicit assumptions explicit, helping stakeholders navigate diverging worldviews and identify opportunities in biotech's evolving landscape.